Fibrinogen and plasminogen modifications during oral estradiol replacement therapy.
OBJECTIVE
To assess the effects of oral E2 replacement therapy on various hemostatic parameters and cardiovascular risk factors in healthy, postmenopausal women.


METHODS
A double-blind, randomized, prospective study comparing the effect of a placebo and of oral micronized E2 (2 mg daily) during a 6-month period. Evaluations were performed before treatment and after 3 and 6 months.


METHODS
Departments of Gynecology, Hemostasis, and Nutrition, Hôtel-Dieu, Paris, France.


METHODS
Thirty-six healthy women with natural or surgical menopause.


RESULTS
Compared with placebo, oral E2 replacement therapy resulted in a significant decrease in fibrinogen and apo B and a significant increase in plasminogen.


CONCLUSIONS
Besides the effects on lipoproteins, oral estrogen replacement therapy modifies parameters involved in coagulation and fibrinolysis.
Conard
J
J
Department of Hemostasis, Hôtel-Dieu, Paris, France.
Gompel
A
A
Pelissier
C
C
Mirabel
C
C
Basdevant
A
A
D000284:Administration, Oral; D000990:Antithrombin III / Q000032:analysis; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D008055:Lipids / Q000097:blood; D017270:Lipoprotein(a) / Q000097:blood; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis*; D011446:Prospective Studies
D008055:Lipids; D017270:Lipoprotein(a); D004958:Estradiol; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen